Literature DB >> 7307429

Renal disease, age, and oxazepam kinetics.

T G Murray, S T Chiang, H H Koepke, B R Walker.   

Abstract

Effects of renal insufficiency and age on oxazepam kinetics were assessed in 13 normal subjects (21 to 72 yr old), four patients with renal insufficiency, and eight patients on hemodialysis. Normal intact oxazepam results were: mean elimination half-life (t1/2), 10 hr; area under the curve (AUC), 6.0 microgram.hr/ml; unbound oxazepam fraction (fup), 3.2%; maximum concentration of unbound oxazepam (Cmax,u), 16 ng/ml; and intrinsic (unbound drug) clearance (Clint), 2.9 l/hr/kg. Less than 1% of the dose was excreted intact in urine. Age differences had no influence on results. In renal insufficiency patients, t1/2 was prolonged to 25 hr, fup increased to 7%, and Cmax,u and Clint were unchanged. Volume of distribution of unbound oxazepam (Vu) increased, thereby prolonging t1/2. In dialysis patients, t1/2 was prolonged to 33 hr, fup increased to 6.2%, and Cmax,u and Clint again were unchanged. Oxazepam was undialyzable; since unbound oxazepam disposition kinetics are not altered, no dosage adjustment for patients is necessary.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307429     DOI: 10.1038/clpt.1981.241

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.

Authors:  J Sennesael; D Verbeelen; L Vanhaelst; R Pirola; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.

Authors:  Paul K L Chin; Berit P Jensen; Helle S Larsen; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 5.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

6.  Bioavailability and pharmacokinetics of oxazepam.

Authors:  J Sonne; S Loft; M Døssing; A Vollmer-Larsen; K L Olesen; M Victor; F Andreasen; P B Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.

Authors:  A M Stijnen; I Postel-Westra; M W Langemeijer; A Hoogerkamp; R A Voskuyl; C F van Bezooijen; M Danhof
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  Disposition of oxazepam in patients on maintenance hemodialysis.

Authors:  H R Ochs; D J Greenblatt; U Klehr
Journal:  Klin Wochenschr       Date:  1984-08-16

Review 9.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of the newer benzodiazepines.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; H R Ochs; R I Shader
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.